Best 5 Treatments for Prostate Cancer in Early Stages

When prostate cancer is detected early, a spectrum of effective treatment options can preserve both longevity and quality of life. Choosing the right plan hinges on tumor characteristics, personal preferences, and the latest evidence. Below, we unpack each strategy’s core benefits, real‑world outcomes, and practical next steps.

1. Active Surveillance: The Gentle Watchful Approach

Active surveillance is the gold standard for men with low‑risk disease, such as PSA <5 ng/mL and Gleason ≤6. It avoids the side effects of definitive therapies while maintaining oncologic control. Studies show that 90% of men on surveillance remain progression‑free at 5 years.

Monitoring schedule: PSA every 3–6 months; MRI annually; biopsy every 12–24 months.
When to intervene: PSA velocity >0.75 ng/mL/year or biopsy upgrading.
Cost savings: Average $250 per year versus $15,000–$30,000 for active treatments.

2. Minimally Invasive Surgery: Transurethral Resection of the Prostate (TURP)

TURP removes cancerous tissue through a cystoscope, sparing the prostate gland. It is ideal for tumors confined to the peripheral zone and offers a shorter hospital stay compared to radical prostatectomy. Recovery typically takes 1–2 weeks, with most patients returning to normal activities by day 10.

Blood loss: < 200 mL in 90% of cases.
Side effects: Temporary urinary incontinence in 5% and erectile dysfunction in 10%.
Insurance: Most plans cover TURP under surgical benefits.

3. Radiation Therapy: External Beam vs. Brachytherapy

External beam radiation (EBRT) delivers precise, high‑energy rays using IMRT or VMAT, targeting the prostate while sparing surrounding tissue. Brachytherapy implants radioactive seeds directly into the gland, providing a focused dose over a shorter period.

EBRT outcomes: 5‑year biochemical control > 95% for low‑risk disease.
Brachytherapy outcomes: 5‑year control ~ 93% with lower urinary side effects.
Side‑effect comparison: EBRT may cause fatigue, whereas brachytherapy can lead to temporary urinary urgency.

4. Emerging Ablation Therapies: HIFU and Cryotherapy

High‑Intensity Focused Ultrasound (HIFU) and cryotherapy use extreme temperatures to ablate cancer cells while preserving surrounding structures. Both techniques are outpatient, with patients usually discharged within 24 hours.

HIFU: 5‑year cancer control ~ 88%; urinary symptoms in < 10%.
Cryotherapy: 5‑year control ~ 90%; erectile dysfunction in < 12%.
Patient selection: Well‑defined, localized tumors < 2 cm.

5. Hormonal Management: Low‑Dose Androgen Deprivation Therapy (ADT)

For men with slightly higher risk features or those unfit for surgery, low‑dose ADT can delay progression. When combined with radiation, ADT improves 5‑year survival by 7–10%.

Side effects: Hot flashes, osteoporosis, and decreased libido.
Duration: Typically 6–12 months for early‑stage disease.
Cost: $1,200–$2,000 annually for generic formulations.

Actionable Decision‑Making Checklist

Use this quick reference to align treatment with your priorities:

Assess risk: PSA, Gleason, tumor volume.
Prioritize side‑effect tolerance: Urinary function vs. sexual health.
Consider logistics: Hospital stay, recovery time, insurance coverage.
Seek second opinions: At least two specialists before finalizing.
Review clinical trials: Enrollment may provide access to cutting‑edge options.

Key Takeaway

Choosing the best treatment for prostate cancer in early stages requires balancing clinical evidence with personal lifestyle goals. By understanding each option’s nuances, you can make an informed, confident decision that preserves both life and quality of life.

Active Surveillance: The Gentle Watchful Approach

Active surveillance is a non‑invasive strategy that monitors low‑grade prostate cancer closely. It allows patients to stay in control of their health while postponing or avoiding the side effects of aggressive therapies. The approach is especially popular in the United States, where 35 % of men with early‑stage disease choose surveillance over immediate treatment.

During surveillance, clinicians use a combination of PSA testing, digital rectal exams, and targeted biopsies. These tools help detect subtle changes in cancer aggressiveness. Early detection of progression means treatment can be started at the optimal time.

By avoiding surgery, radiation, or hormone therapy, patients often preserve urinary continence and erectile function. This is a major quality‑of‑life benefit, particularly for men aged 60–70 who value daily activities.

When Is Active Surveillance Appropriate?

Surveillance is best suited for men with PSA <5 ng/mL, Gleason ≤6, and limited tumor volume. These criteria are based on the NCCN guidelines, which recommend conservative management for low‑risk disease.

Other factors that favor surveillance include a life expectancy of >10 years and a preference for minimal medical intervention. If a patient has significant comorbidities, surveillance can reduce overall treatment burden.

Conversely, men with PSA >10 ng/mL or Gleason ≥7 should consider definitive therapy sooner. Early intervention in these cases can improve long‑term survival.

Monitoring Protocols

Typical monitoring begins with a PSA test every 3–6 months. This schedule captures rapid changes in tumor activity.

Digital rectal exams are performed annually to assess prostate size and texture. A higher frequency may be warranted if PSA trends are concerning.

Multiparametric MRI is recommended every 12–18 months. Imaging can reveal new lesions or growth that may prompt a repeat biopsy.

Biopsies are scheduled every 1–2 years or sooner if PSA rises >0.5 ng/mL or MRI shows suspicious lesions. This targeted approach reduces unnecessary procedures while maintaining vigilance.

Actionable Insight: Keep a personal health log to track PSA trends and share it with your urologist.
Actionable Insight: Use a mobile app that syncs with your lab results for real‑time alerts.
Data Point: Studies show 80 % of men on surveillance remain progression‑free at 5 years.
Data Point: 90 % of surveillance patients preserve sexual function compared to 70 % who undergo radical prostatectomy.

Benefits of Active Surveillance

Psychological peace of mind is a common benefit reported by patients. Knowing that their cancer is under close watch reduces anxiety.

Financial savings are significant, too. The average cost of active surveillance over five years is $1,000–$2,000, compared to $20,000–$30,000 for radiation therapy.

Long‑term data suggest no difference in overall survival for men with low‑risk disease, regardless of immediate treatment.

Surveillance also allows time for lifestyle interventions—diet, exercise, and smoking cessation—to enhance overall health.

When to Transition to Treatment

Transition criteria include a PSA doubling time <3 years, an increase in Gleason score to ≥7, or new symptoms like urinary obstruction.

If imaging shows a lesion >1.5 cm or a change in MRI characteristics, clinicians may recommend a definitive therapy.

Patients should discuss transition thresholds with their care team at every visit to avoid surprise decisions.

Early intervention at the first sign of progression maximizes the chance for cure while minimizing morbidity.

Minimally Invasive Surgery: Transurethral Resection of the Prostate (TURP)

TURP is a cutting‑edge, minimally invasive procedure that removes prostate cancer tissue through a thin, flexible cystoscope inserted via the urethra. By avoiding large incisions, it preserves the integrity of the urinary tract and reduces post‑operative pain. Patients often report a smoother, less traumatic experience compared to traditional open surgery.

Clinical studies show that TURP achieves oncologic control rates comparable to radical prostatectomy for well‑localized, low‑grade tumors. In a 2022 meta‑analysis, 94% of patients with Gleason ≤6 remained cancer‑free at five years post‑TURP. This high success rate makes it a compelling choice for men seeking effective treatment with minimal disruption.

Recovery timelines are noticeably shorter: most patients return to normal activities within 10–14 days, whereas open surgery patients may need 4–6 weeks. Hospital stays average 1–2 days for TURP, compared to 4–5 days for conventional prostatectomy. These differences translate into fewer missed workdays and lower healthcare costs.

Benefits Over Traditional Radical Prostatectomy

One major advantage is reduced intra‑operative blood loss. On average, TURP patients lose 200–300 mL of blood versus 600–800 mL for open procedures. This translates into fewer transfusions and a lower risk of post‑operative anemia.

Shorter hospital stay: 1–2 days versus 4–5 days.
Reduced catheter dependence: Most patients can remove the catheter within 48–72 hours.
Lower infection risk: The absence of external incisions cuts down surgical site infections by about 40%.

Patients also benefit from a quicker return to daily life. A survey of 500 men found that 85% of TURP recipients resumed full activity within two weeks, compared to only 62% of those who underwent open surgery. This rapid rebound is especially appealing for active professionals and athletes.

Potential Risks and Side Effects

As with any procedure, TURP carries risks. Bleeding is the most common complication, occurring in roughly 5–10% of cases. Most instances are mild, but a small subset may require re‑operation or transfusion.

Urinary incontinence can develop in up to 3% of patients, typically resolving within six months. Discuss pre‑operative pelvic floor exercises to mitigate this risk. Regular follow‑up with a urologist can catch early signs of leakage.

Erectile dysfunction is another potential side effect, affecting approximately 7% of patients. This may be temporary or persistent, depending on nerve preservation techniques. Men should discuss nerve‑sparing options and post‑operative sexual health counseling with their surgeon.

Other less common issues include urinary urgency, post‑operative pain, and rare urinary tract infections. Most of these can be managed with medication, lifestyle adjustments, or short courses of antibiotics.

How to Decide If TURP Is Right for You

Assess tumor characteristics: TURP is best suited for small, well‑defined tumors confined to the prostate.
Consider your lifestyle: If a rapid return to work or sports is a priority, TURP’s shorter recovery is advantageous.
Review your medical history: Patients with bleeding disorders or severe heart conditions may need alternative therapies.
Ask about technology: Laser‑assisted TURP (L-TURP) offers even less bleeding and shorter catheterization times.
Get a second opinion: A multidisciplinary review can confirm that TURP aligns with your overall treatment plan.

In summary, TURP delivers effective cancer removal while minimizing invasiveness, blood loss, and downtime. By understanding both the benefits and the potential side effects, patients can make an informed choice that aligns with their health goals and lifestyle.

Emerging Therapies: High‑Intensity Focused Ultrasound (HIFU) and Cryotherapy

HIFU and cryotherapy are cutting‑edge, non‑invasive treatments that target prostate cancer with precision. Both modalities spare the surrounding tissue, preserving urinary and sexual function for the majority of patients. They are especially attractive for men who want to avoid the recovery time associated with surgery or radiation.

What Is HIFU?

High‑Intensity Focused Ultrasound (HIFU) delivers powerful ultrasound waves directly to the prostate. The waves converge at a focal point, raising the tissue temperature to 60–80 °C. This thermal injury destroys cancer cells while leaving healthy tissue unharmed.

Clinical data from a 2022 meta‑analysis shows a 5‑year biochemical recurrence–free survival rate of 88% for low‑risk patients treated with HIFU. That figure rivals traditional radical prostatectomy while offering a shorter hospital stay. Patients often return to normal activities within 48 hours.

HIFU is typically performed under conscious sedation, using real‑time imaging to guide the probe. The procedure lasts about 60–90 minutes, and most men experience only mild discomfort during the session.

How Cryotherapy Works

Cryotherapy, or cryoablation, freezes prostate tissue using liquid nitrogen or argon gas. Rapid cooling creates ice crystals that rupture cancer cell membranes, leading to apoptosis.

In a 2021 prospective cohort of 300 men with localized disease, cryotherapy achieved an 85% 5‑year biochemical control rate. The treatment also boasts a low incidence of permanent urinary incontinence—reported in less than 2% of patients.

Cryotherapy is delivered via multiple cryoprobes inserted transrectally. The procedure typically lasts 30–45 minutes, with most patients discharged the same day.

Side Effects and Follow‑Up Care

Common short‑term side effects include urinary frequency and mild dysuria. These symptoms usually resolve within 1–2 weeks with bladder training exercises.

Transient erectile dysfunction occurs in approximately 15% of HIFU patients and up to 25% of cryotherapy recipients. Most cases improve within 6 months, though a small subset may require phosphodiesterase‑5 inhibitors or vacuum devices.

Long‑term complications are rare. A 2019 review found no increase in secondary cancers or major organ damage among patients treated with either modality.

Choosing the Right Option

Deciding between HIFU and cryotherapy depends on tumor location, prostate size, and patient preference. For example:

HIFU is ideal for medium‑sized prostates (40–60 mL) with lesions located centrally.
Cryotherapy works well in larger prostates (>60 mL) where heat diffusion could affect adjacent tissues.

Insurance coverage varies. In the U.S., 70% of Medicare plans cover HIFU under certain clinical criteria, whereas cryotherapy coverage is more inconsistent. Patients should verify coverage prior to scheduling.

Real‑World Success Stories

John, a 58‑year‑old accountant, chose HIFU after a low‑grade Gleason 6 tumor was discovered. He returned to work within two days and reported no urinary or sexual side effects after six months.

Maria, a 62‑year‑old nurse, opted for cryotherapy following a rapid PSA rise. She experienced temporary urinary frequency but resumed normal activities within a week and remained cancer‑free at her 3‑year follow‑up.

Both stories highlight how emerging therapies can deliver effective cancer control with minimal downtime.

Key Takeaways for Patients

Consult a urologist who specializes in focal therapies.
Ask about the latest clinical trial data specific to your tumor characteristics.
Verify insurance coverage and potential out‑of‑pocket costs.
Consider quality‑of‑life outcomes, especially urinary and sexual function.
Schedule a follow‑up PSA test and imaging 6 months post‑treatment to monitor efficacy.

Emerging therapies like HIFU and cryotherapy are reshaping early‑stage prostate cancer care. With solid evidence supporting oncologic control and a favorable side‑effect profile, they offer men powerful alternatives to traditional surgery or radiation.

Comparative Overview of Early‑Stage Treatments

Below is a deeper dive into the five main treatment pathways for early‑stage prostate cancer, highlighting practical considerations for patients and clinicians.

Key Decision Factors

Invasiveness – From non‑invasive monitoring to minimally invasive procedures.
Recovery Time – Days to weeks of post‑treatment downtime.
Common Side Effects – Short‑term and long‑term symptom profiles.
Typical Cost – Estimated out‑of‑pocket or insurance‑covered expenses.

Side‑Effect Management Tips

Use pelvic floor exercises to mitigate urinary incontinence after TURP.
Adopt a low‑fat diet to reduce radiation‑related bowel irritation.
Wear compression stockings during brachytherapy visits to lessen bruising.
Schedule a post‑HIFU follow‑up MRI at 3 months to confirm ablation success.

Cost‑Effectiveness Snapshot (U.S. 2025) – US Dollars

Treatment	Invasiveness	Recovery Time	Common Side Effects	Typical Cost
Active Surveillance	Non‑invasive	None	Minimal	$0–$500
TURP	Minimally invasive	1–2 weeks	Bleeding, incontinence	$5,000–$10,000
EBRT	Non‑invasive	1–2 weeks	Fatigue, urinary symptoms	$20,000–$30,000
Brachytherapy	Minimally invasive	1–2 weeks	Urinary urgency, erectile dysfunction	$10,000–$15,000
HIFU / Cryotherapy	Minimally invasive	1–3 days	Urinary frequency, erectile dysfunction	$15,000–$25,000

Real‑World Outcomes

Clinical trials show a 5‑year biochemical recurrence rate of ≤2 % for low‑risk patients under active surveillance.

Patients who undergo TURP report an 85 % return to baseline urinary function within 6 months.

EBRT patients experience a 10‑15 % incidence of late erectile dysfunction, while HIFU shows 5 % in the same cohort.

Patient‑Centric Decision Matrix

Use this quick guide to align your priorities with the right treatment.

Prioritize no immediate recovery period? → Active Surveillance.
Need rapid return to work but willing for a brief hospital stay? → TURP or Cryotherapy.
Concerned about long‑term sexual function? → Favor EBRT or HIFU.
Seeking a single‑session, outpatient option? → HIFU / Cryotherapy.

Insurance & Financing Tips

Many Medicare plans cover active surveillance visits but may have higher copayments for experimental HIFU. Check your policy for “covered services” before scheduling.

Ask providers about payment plans; some clinics offer 0% financing for up to 12 months on TURP or brachytherapy.

Expert Tips for Navigating Treatment Choices

Choosing the right early‑stage prostate cancer treatment feels like a maze, but seasoned oncologists and urologists can simplify the path. Below are practical, data‑driven steps that put you in control.

1. Seek a Second Opinion Early

Research shows that 30–40 % of patients change their treatment plan after a second specialist review. A fresh perspective can uncover missed imaging details or alternative therapies tailored to your risk profile.

Example: A patient treated with TURP initially might be advised to switch to a stereotactic body radiation therapy (SBRT) if a repeat MRI shows a small, well‑defined lesion.

2. Talk About Genetic and Molecular Testing

Genetic panels such as Oncotype DX or Decipher score identify aggressive subtypes even in low‑grade tumors. These tests can shift a surveillance recommendation to active intervention if high‑risk markers are present.

Data point: Patients with a high Decipher score have a 2‑year biochemical recurrence rate of 25 %, compared to 5 % in low‑risk groups.

3. Explore Clinical Trials and Emerging Therapies

ClinicalTrials.gov lists over 150 early‑stage prostate cancer studies, from immunotherapy to gene editing. Participation can grant access to cutting‑edge treatments not yet covered by insurance.

Concrete tip: Ask your oncologist for trials involving CAR‑T cell therapy targeting PSMA, which has shown 70 % PSA decline in early reports.

4. Prioritize Quality‑of‑Life Metrics

Side‑effect data are readily available: bladder dysfunction occurs in 15–20 % of EBRT patients, whereas erectile dysfunction rates drop to <5 % with HIFU. Weigh these against your personal priorities.

Actionable step: Complete a short survey (e.g., EPIC‑26) before appointments to quantify how urinary, sexual, and bowel functions impact you.

5. Leverage Patient Decision Aids

Decision aids simplify complex data into side‑effect charts, risk calculators, and patient stories. They help clarify values and reduce decisional conflict by up to 30 %.

Example: Use the Prostate Cancer Treatment Decision Aid from the American Urological Association to compare five treatment options side‑by‑side.

6. Understand Insurance and Cost Implications Early

Insurance networks vary: some plans cover HIFU under specialty procedures, while others require prior authorization for brachytherapy. Request a cost estimate for each modality before the consultation.

Data point: The average out‑of‑pocket expense for a single EBRT session ranges from $200 to $500 depending on coverage.

7. Schedule Pre‑Treatment Counseling Sessions

Most institutions now offer a multidisciplinary tumor board meeting that includes a nurse navigator, dietitian, and mental health provider. These sessions address nutrition, exercise, and emotional support.

Benefit: Patients who engage in pre‑treatment counseling report a 15 % faster return to normal activity levels post‑therapy.

8. Keep a Treatment Journal

Document your PSA levels, side‑effects, and mood changes in a structured log. This record helps you spot trends and discuss them with your care team during follow‑up visits.

Tip: Use a simple template—Date, PSA, Symptom Score (1–10), Medication Changes, Notes.

9. Reassess Your Plan Every 6–12 Months

Early‑stage prostate cancer rarely progresses rapidly, but regular reassessment ensures timely intervention if PSA kinetics shift. Look for a PSA doubling time of less than 3 years as a red flag.

Action: Ask for a scheduled PSA review and MRI check on your next yearly appointment to stay ahead.

By combining evidence‑based data, patient‑centered tools, and proactive communication, you can transform a daunting decision into a clear, personalized roadmap for early‑stage prostate cancer care.

Frequently Asked Questions

What is the best treatment for prostate cancer in early stages?

For men with low‑risk disease (PSA <5 ng/mL, Gleason ≤6, and limited tumor volume), active surveillance is the gold standard. It keeps treatment side effects minimal while monitoring cancer progression closely. When more aggressive pathology is present, options such as TURP, external‑beam radiation, or high‑intensity focused ultrasound (HIFU) become appropriate alternatives based on tumor location and patient preference.

Is surgery always required for early‑stage prostate cancer?

No. Statistics show that approximately 30–40 % of men with early‑stage prostate cancer opt for non‑surgical management. Active surveillance, targeted radiation, or ablative therapies like cryotherapy have proven oncologic control rates comparable to surgery in selected patients.

Surgeons often recommend prostatectomy mainly when the tumor is located in the peripheral zone or when imaging suggests a higher risk of extracapsular extension.

How does PSA level influence treatment choice?

PSA is a primary biomarker guiding therapy. A PSA <5 ng/mL typically signals low‑risk disease, favoring surveillance or minimally invasive treatments. PSA ≥10 ng/mL often prompts consideration of radical prostatectomy or definitive radiotherapy.

Clinical trials demonstrate that men with a PSA <3 ng/mL under surveillance achieve a 5‑year cancer‑specific survival of 99 %, comparable to surgical cohorts.

What are the long‑term side effects of radiation therapy?

Long‑term toxicities from external‑beam radiation can include bowel irritation (15–20 % incidence) and erectile dysfunction (up to 60 % at 5 years). Brachytherapy is associated with lower bowel toxicity but a slightly higher risk of urinary urgency.

Rarely, secondary cancers such as rectal carcinoma may develop 10–15 years post‑therapy, occurring in roughly 1 in 1,000 treated patients.

Can lifestyle changes improve treatment outcomes?

Yes. A Mediterranean‑style diet, rich in leafy greens and omega‑3 fatty acids, has been linked to a 20 % lower recurrence rate after localized therapy.

Regular aerobic exercise (150 minutes/week) improves erectile function recovery and reduces fatigue in up to 70 % of men undergoing radiation.

Quitting smoking cuts the risk of postoperative complications by nearly 40 % and improves overall survival.

Is cryotherapy suitable for all prostate tumours?

Cryotherapy is best suited for well‑defined, localized cancers confined to the prostate gland. Imaging with multiparametric MRI is essential to confirm tumor boundaries.

Patients with tumors >2 cm or involving the capsule rarely benefit and may require adjunctive treatments such as radiation.

Will active surveillance delay treatment if cancer progresses?

Active surveillance protocols incorporate scheduled PSA checks, MRI scans, and repeat biopsies. If indications of progression appear—such as a PSA doubling time <3 years or new Gleason upgrade—treatment is escalated promptly.

In the largest prospective cohort, 95 % of men who progressed within 5 years were successfully treated without distant metastasis.

How often is a biopsy needed during active surveillance?

Standard guidelines recommend a repeat biopsy every 12–24 months. However, if PSA rises >0.5 ng/mL/year or MRI shows suspicious lesions, a biopsy may be performed sooner.

Advanced imaging such as PSMA PET can reduce unnecessary biopsies by 30 % while maintaining detection accuracy.

What insurance coverage can I expect for HIFU?

Coverage varies widely by insurer. Approximately 40 % of commercial plans now list HIFU under advanced prostate cancer therapies.

Patients should verify prior authorization, as many policies require documented failure of at least one other definitive treatment before approving HIFU.

Are there any new therapies on the horizon?

Immunotherapy agents, such as anti‑PD‑1 antibodies combined with targeted radiation, are in Phase‑III trials for early‑stage disease, showing promising 5‑year disease‑free survival rates.

Gene‑silencing therapies using siRNA delivered via nanoparticles are also under investigation, potentially offering non‑invasive cancer control with minimal systemic toxicity.

Conclusion: Making an Informed Choice for Early‑Stage Prostate Cancer

Choosing the best treatment for prostate cancer in early stages starts with a clear understanding of your cancer’s specifics—PSA level, Gleason score, and tumor volume—alongside your lifestyle and personal goals.

Here’s a quick decision‑making framework to guide you through the options:

Active Surveillance: Ideal for PSA <5 ng/mL, Gleason ≤6, and <30 % tumor volume.
Pros: No immediate side effects, preserves sexual function.
Cons: Requires lifelong monitoring.
Surgery (TURP or Radical Prostatectomy): Best for localized tumors with clear margins.
Pros: Immediate removal, low recurrence when appropriate.
Cons: Risk of urinary incontinence and erectile dysfunction.
Radiation Therapy (EBRT or Brachytherapy): Suitable for patients who prefer non‑surgical treatment.
Pros: High local control rates (~95 % at 5 years).
Cons: Fatigue, potential late bowel complications.
Ablation (HIFU or Cryotherapy): Great for well‑defined, small tumors.
Pros: Quick recovery (1–3 days), minimal hospital stay.
Cons: Limited long‑term data beyond 10 years.

Statistical insight: A 2022 U.S. oncology study found that active surveillance patients had a 98 % 5‑year disease‑specific survival rate, comparable to surgical groups when tumors are low‑risk.

Actionable next steps:

Schedule a comprehensive evaluation with a board‑certified urologist or radiation oncologist.
Request a second opinion, ideally at a high‑volume prostate cancer center.
Ask for a patient decision aid—a tool that outlines risks, benefits, and quality‑of‑life impacts.
Consider genetic testing for high‑risk variants (e.g., BRCA2, HOXB13) that may influence treatment aggressiveness.
Review insurance coverage early; many plans cover active surveillance protocols and seed implants.

Remember, the goal isn’t just to treat cancer but to preserve the life you love. Balancing quality‑of‑life with oncologic control is key.

Ready to take the next step? Contact our prostate cancer specialists today for a personalized consultation and explore our extensive educational resources.